Fox Chase, Sylvester collaborate with Pfizer to identify genetic drivers of cancer disparities

Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study finds

Pfizer Inc. announced positive results from the phase III TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, demonstrating a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.

February 14, 2025

Vol.51 No.06

In Brief

Weiran Feng, Hanzhi Luo, Qing Chen join Fox Chase Cancer Center as assistant professors

Weiran FengHanzhi LuoQing ChenWeiran Feng, Hanzhi Luo and Qing Chen will join Fox Chase Cancer Center as assistant professors.

January 31, 2025

Vol.51 No.04

In Brief

Roland Dunbrack appointed co-leader of Cancer Signaling and Microenvironment Research Program at Fox Chase

Roland Dunbrack was named co-leader of the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center alongside the program’s current leader, Edna Cukierman.

January 17, 2025

Vol.51 No.02

In Brief

UH Cancer Center and John A. Burns School of Medicine form initiative focused on health outcome disparities in Hawai‘i and the Pacific

The University of Hawai‘i Cancer Center and the John A. Burns School of Medicine are forming Ka ʻUmeke Lama, an initiative to transform cancer care in Hawaiʻi and the Pacific.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Ibrance + standard-of-care extends median PFS by over 15 months in HR+, HER2+ metastatic breast cancer, phase III trial shows

The phase III PATINA trial demonstrated that the addition of Ibrance (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival by investigator assessment in patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer.

January 10, 2025

Vol.51 No.01

Drugs & Targets

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

FDA granted accelerated approval to encorafenib (Braftovi) with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.

January 10, 2025

Vol.51 No.01

Fox Chase, Sylvester collaborate with Pfizer to identify genetic drivers of cancer disparities

YOU MAY BE INTERESTED IN

Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study finds

Weiran Feng, Hanzhi Luo, Qing Chen join Fox Chase Cancer Center as assistant professors

Roland Dunbrack appointed co-leader of Cancer Signaling and Microenvironment Research Program at Fox Chase

UH Cancer Center and John A. Burns School of Medicine form initiative focused on health outcome disparities in Hawai‘i and the Pacific

Ibrance + standard-of-care extends median PFS by over 15 months in HR+, HER2+ metastatic breast cancer, phase III trial shows

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

Renew today!

Subscriber content

Never miss an issue!

Login